{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:59:35Z","timestamp":1761487175612},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1016\/j.ygyno.2004.05.002","type":"journal-article","created":{"date-parts":[[2004,6,22]],"date-time":"2004-06-22T14:23:17Z","timestamp":1087914197000},"page":"578-580","source":"Crossref","is-referenced-by-count":7,"title":["Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn"],"prefix":"10.1016","volume":"94","author":[{"given":"Maurie","family":"Markman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kulp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertrude","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2004.05.002_BIB1","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase: III. Study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.002_BIB2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1006\/gyno.2000.5819","article-title":"Phase: II. Study of liposomal doxorubicin in advanced gynecologic cancers","volume":"78","author":"Israel","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.002_BIB3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase: II. Study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.002_BIB4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/gyno.2000.5921","article-title":"Phase: 2. Trial of liposomal doxorubicin (40 mg\/m2) in platinum\/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum","volume":"78","author":"Markman","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.002_BIB5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1006\/gyno.2000.5980","article-title":"The clinical utility of liposomal doxorubicin in recurrent ovarian cancer","volume":"81","author":"Campos","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.002_BIB6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/gyno.2001.6272","article-title":"Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages","volume":"82","author":"Rose","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.002_BIB7","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1995.13.7.1777","article-title":"Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase: I. Studies","volume":"13","author":"Uziely","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.002_BIB8","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.1997.15.10.3185","article-title":"Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase: II. Trial","volume":"15","author":"Ranson","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.002_BIB9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1023\/A:1008319618638","article-title":"Phase: I. Study of calyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer","volume":"11","author":"Caponigro","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.002_BIB10","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (doxil) in metastatic breast carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2004.05.002_BIB11","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2165\/00003495-199753030-00011","article-title":"Polyethylene glycol-liposomal doxorubicin","volume":"53","author":"Coukell","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.ygyno.2004.05.002_BIB12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.7326\/0003-4819-101-6-798","article-title":"Chemotherapy-associated palmar\u2013plantar erythrodysesthesia syndrome","volume":"101","author":"Lokich","year":"1984","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ygyno.2004.05.002_BIB13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","article-title":"Antineoplastic therapy-induced palmar plantar erythrodysesthesia (\u2018hand\u2013foot\u2019) syndrome. Incidence, recognition and management","volume":"1","author":"Nagore","year":"2000","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.ygyno.2004.05.002_BIB14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s002800050591","article-title":"Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors","volume":"39","author":"Vail","year":"1997","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2004.05.002_BIB15","first-page":"1567","article-title":"Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (stealth) liposomes: a randomized, double-blind clinical trial using a canine model","volume":"4","author":"Vail","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2004.05.002_BIB16","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/85.17.1432","article-title":"Pyridoxine therapy for palmar\u2013plantar erythrodysesthesia associated with taxotere","volume":"85","author":"Vukelja","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2004.05.002_BIB17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00216925","article-title":"Pyridoxine therapy for palmar\u2013plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion","volume":"8","author":"Fabian","year":"1990","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ygyno.2004.05.002_BIB18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00432-003-0497-8","article-title":"Phase: 2. Trial of liposomal doxorubicin in advanced endometrial cancer","volume":"129","author":"Escobar","year":"2003","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.002_BIB19","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/1097-0142(197509)36:3<946::AID-CNCR2820360316>3.0.CO;2-5","article-title":"Radiation\u2013adriamycin interactions: preliminary clinical observations","volume":"36","author":"Cassady","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2004.05.002_BIB20","first-page":"224","article-title":"Radiation recall associated with VP-16-213 therapy","volume":"63","author":"Fontana","year":"1979","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.ygyno.2004.05.002_BIB21","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/1097-0142(19930215)71:4<1322::AID-CNCR2820710425>3.0.CO;2-Z","article-title":"Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome","volume":"71","author":"Stelzer","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2004.05.002_BIB22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/A:1014421912799","article-title":"Chemotherapy-induced palmar\u2013plantar erythrodysesthesia syndrome\u2014Recall following different chemotherapy agents","volume":"20","author":"Hui Fung","year":"2002","journal-title":"Invest. New Drugs"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825804003117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825804003117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T19:57:13Z","timestamp":1549483033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825804003117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0090825804003117"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2004.05.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}